Q4 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for OmniAb in a research note issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2029 earnings at ($0.29) EPS.

Separately, Benchmark reduced their price objective on OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday.

OmniAb Stock Performance

OmniAb stock opened at $2.53 on Friday. The firm has a market cap of $357.28 million, a P/E ratio of -4.08 and a beta of -0.14. The business’s fifty day moving average is $3.34 and its two-hundred day moving average is $3.77. OmniAb has a 52 week low of $2.23 and a 52 week high of $5.63.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $10.13 million. During the same period in the prior year, the business posted ($0.14) earnings per share.

Insider Activity

In related news, insider Charles S. Berkman sold 25,489 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. This represents a 6.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Kurt A. Gustafson sold 15,526 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $50,304.24. Following the completion of the sale, the chief financial officer now owns 212,720 shares of the company’s stock, valued at $689,212.80. This represents a 6.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 over the last 90 days. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OABI. Hsbc Holdings PLC bought a new stake in shares of OmniAb in the fourth quarter worth about $38,000. Choreo LLC bought a new stake in shares of OmniAb in the fourth quarter worth about $41,000. Rangeley Capital LLC bought a new stake in shares of OmniAb in the fourth quarter worth about $41,000. KLP Kapitalforvaltning AS bought a new stake in shares of OmniAb in the fourth quarter worth about $49,000. Finally, Walleye Capital LLC bought a new stake in shares of OmniAb in the third quarter worth about $61,000. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.